Neuroendocrine carcinoma metastatic
Not yet recruitingA study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.
A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.
- Disease:Neuroendocrine carcinoma metastatic
- Substances:Zimberelimab
France- Participants:18–64 years · 65+ years
- Substances:Zimberelimab












